Tetsuji Naka

ナカテツジ | Tetsuji Naka

Affiliation and department：
Other affiliations (1)：

国立研究開発法人医薬基盤・健康・栄養研究所招聘シニアプロジェクトリーダー

Research field (3)： Tumor diagnostics and therapeutics , Respiratory medicine , Allergies and connective tissue disease

Research keywords (3)： antibody , gene therapy , cytokine signaling

Research theme for competitive and other funds (20)：

2022 - 2025 抗癌剤の薬効を増強できる抗体を用いた抗体薬物複合体による卵巣癌治療薬
2020 - 2023 頭頸部扁平上皮癌におけるSOCS1新規遺伝子治療確立のための基礎研究
2017 - 2020 Investigation of the mechanism of LRG, a novel inflammatory molecule, in modulating TGF-beta signaling for the development of therapy in rheumatic diseases
2016 - 2018 Functional analysis of LSR and development of innovative therapy for ovarian cancer stem cells.
2015 - 2017 The role of leucine-rich alpha2 glycoprotein in cardiac remodeling

2015 - 2017 Analysis of the role for human herpesvirus 6 gM/gN entry

2014 - 2017 Investigation of regulatory mechanism of secretary protein kinase and its application for treatment of rheumatoid arthritis

2014 - 2017 Drug screening and identification of biomarkers using sensitivity assay with a panel of primary cultured cancer spheroids derived from endometrial cancer

2013 - 2016 Identification of molecular characteristics in serous carcinoma of Mullerian origin

2013 - 2016 Proteomic screening for malignant melanoma antigen and development of antibody-based medicine for metastasis.

2010 - 2012 Study on the function of a novel inflammatorymarker protein(LRG) in the pathogenes I s of autoimmune d I sorders

2009 - 2009 プロテオミクス手法による抗体医薬品奏功性を予測する血清バイオマーカーの探索

2007 - 2009 Role of glycosylation in the oncogenesis of gastrointestinal sarcoma

2006 - 2007 間葉系腫瘍に於ける細胞内シグナル伝達系活性化と腫瘍増殖機構の解明

2005 - 2006 Prediction of onset of allergic diseases through analysis of single nucleotide polymorphisms and prevention of onset of allergic diseases by an appropriate intake of flavonoids

2003 - 2004 Investigation on the role of SOCS family in the development of lung cancer. and its application to cancer therapy

2002 - 2004 New gene therapy for lung cancer by suppressor of cytokine signaling-1

2001 - 2003 Approaches to the pathogenesis of bronchial asthma

2001 - 2001 感染と宿主応答におけるJAK/STAT制御蛋白の役割の解明

1999 - 2000 Clarification of Negative Feedback Mechanism in Cytokine Signaling by Using SSI-1 KO Mouse

Show all

Papers (251)：

Masashi Funauchi, Satoshi Serada, Kosuke Hiramatsu, Eiji Funajima, Mizuki Kanda, Yoshikazu Nagase, Satoshi Nakagawa, Tomoharu Ohkawara, Minoru Fujimoto, Yuji Suzuki, et al. Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function. International journal of cancer. 2024. 154. 3. 425-433
Ryugo Teranishi, Tsuyoshi Takahashi, Yuuki Obata, Toshirou Nishida, Shuichi Ohkubo, Hiromi Kazuno, Yurina Saito, Satoshi Serada, Minoru Fujimoto, Yukinori Kurokawa, et al. Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors. International journal of cancer. 2023. 152. 12. 2580-2593
Mizuki Kanda, Satoshi Serada, Kosuke Hiramatsu, Masashi Funauchi, Kengo Obata, Satoshi Nakagawa, Tomoharu Ohkawara, Okinori Murata, Minoru Fujimoto, Fumiko Chiwaki, et al. Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer. Neoplasia. 2023. 35. 100853-100853
Yoshikazu Nagase, Kosuke Hiramatsu, Masashi Funauchi, Mayu Shiomi, Tatsuo Masuda, Mamoru Kakuda, Satoshi Nakagawa, Ai Miyoshi, Shinya Matsuzaki, Eiji Kobayashi, et al. Anti-lipolysis-stimulated lipoprotein receptor monoclonal antibody as a novel therapeutic agent for endometrial cancer. BMC Cancer. 2022. 22. 1
Tsukie Kin Tsukuda, Hiroshi Ohnishi, Minoru Fujimoto, Yu Nakatani, Kazufumi Takamatsu, Tetsuji Naka, Akihito Yokoyama. Lung CCR6-CXCR3- type 2 helper T cells as an indicator of progressive fibrosing interstitial lung diseases. Scientific Reports. 2022. 12. 1. 19577-19577

ｍore...

MISC (240)：

Yuka Shibata, Hideki Nakajima, Kimiko Nakajima, Satoshi Serada, Minoru Fujimoto, Tetsuji Naka, Shigetoshi Sano. Leucine-rich alpha-2 glycoprotein is a predictive marker of therapeutic efficacy of the biologics in psoriatic arthritis. JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY. 2021. 4. 4. 87-89
Biomarkers for inflammatory bowel disease. 2020. 7. 2. 122-127
梁井俊一, 新崎信一郎, 松岡克善, 水野慎大, 飯島英樹, 仲哲治, 金井隆典. 炎症性腸疾患におけるLRGとアダリムマブ血中濃度の関係-Planet studyサブ解析-. 日本消化器病学会雑誌(Web). 2020. 117
梶本恵津子, 藤本穣, 松崎慎哉, 遠藤誠之, 世良田聡, 木村正, 仲哲治. 新規炎症マーカーであるLRG(leucine richα2 glycoprotein)の子宮内胎児感染における有用性. 日本臨床免疫学会総会プログラム・抄録集. 2018. 46回. 132-132
飯島英樹, 松岡克善, 新崎信一郎, 世良田聡, 水野慎大, 藤本穰, 金井隆典, 仲哲治. 【Immunology〜領域を超えた挑戦〜】IBD領域炎症性腸疾患の新たなバイオマーカー leucine-rich α2 glycoprotein(LRG)について. クリニシアン. 2018. 65. 10. 940-945

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page